Stock Analysis
Divi's Laboratories (NSE:DIVISLAB) Full Year 2024 Results
Key Financial Results
- Revenue: ₹78.5b (up 1.0% from FY 2023).
- Net income: ₹16.0b (down 12% from FY 2023).
- Profit margin: 20% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: ₹60.27 (down from ₹68.71 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Divi's Laboratories Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.
Performance of the market in India.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Divi's Laboratories.
Valuation is complex, but we're helping make it simple.
Find out whether Divi's Laboratories is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're helping make it simple.
Find out whether Divi's Laboratories is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:DIVISLAB
Divi's Laboratories
Engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, North America, Asia, Europe, and internationally.
Flawless balance sheet with reasonable growth potential and pays a dividend.